First reported 11 hours ago -
Updated 11 hours ago -
A planned change to the distribution system for bevacizumab
, trastuzumab, and rituximab could adversely impact patient care, ASHP CEO Paul W. Abramowitz told Genentech CEO Ian T. Clark today.ASHP noted that the current supply chain effectively addresses ...
[Published ASHP - 11 hours ago]